Effect of Vitamin K Supplementation on Insulin Resistance in Older Men and Women

  1. Makiko Yoshida, PHD1,
  2. Paul F. Jacques, SCD1,
  3. James B. Meigs, MD, MPH2,
  4. Edward Saltzman, MD1,
  5. M. Kyla Shea, PHD1,
  6. Caren Gundberg, PHD3,
  7. Bess Dawson-Hughes, MD1,
  8. Gerard Dallal, PHD1 and
  9. Sarah L. Booth, PHD1
  1. 1Jean Mayer U.S. Department of Agriculture Human Nutrition Research Center, Tufts University, Boston, Massachusetts
  2. 2General Medicine Division and Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
  3. 3Yale University School of Medicine, Department of Orthopaedics, New Haven, Connecticut
  1. Corresponding author: Sarah L. Booth, sarah.booth{at}tufts.edu

Abstract

OBJECTIVE—Vitamin K has a potentially beneficial role in insulin resistance, but evidence is limited in humans. We tested the hypothesis that vitamin K supplementation for 36 months will improve insulin resistance in older men and women.

RESEARCH DESIGN AND METHODS—This was an ancillary study of a 36-month, randomized, double-blind, controlled trial designed to assess the impact of supplementation with 500 μg/day phylloquinone on bone loss. Study participants were older nondiabetic men and women (n = 355; aged 60–80 years; 60% women). The primary outcome of this study was insulin resistance as measured by homeostasis model assessment (HOMA-IR) at 36 months. Fasting plasma insulin and glucose were examined as the secondary outcomes.

RESULTS—The effect of 36-month vitamin K supplementation on HOMA-IR differed by sex (sex × treatment interaction P = 0.02). HOMA-IR was statistically significantly lower at the 36-month visit among men in the supplement group versus the men in the control group (P = 0.01) after adjustment for baseline HOMA-IR, BMI, and body weight change. There were no statistically significant differences in outcome measures between intervention groups in women.

CONCLUSIONS—Vitamin K supplementation for 36 months at doses attainable in the diet may reduce progression of insulin resistance in older men.

Footnotes

  • Published ahead of print at http://care.diabetesjournals.org on 12 August 2008.

    Clinical trial reg. no. NCT00183001, clinicaltrials.gov.

    Any opinions, findings, conclusion, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the U.S. Department of Agriculture.

    Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

    • Accepted August 6, 2008.
    • Received July 1, 2008.
« Previous | Next Article »Table of Contents

This Article

  1. Published online before print August 12, 2008, doi: 10.2337/dc08-1204 Diabetes Care November 2008 vol. 31 no. 11 2092-2096
  1. » Abstract
  2. Full Text
  3. Full Text (PDF)
  4. All Versions of this Article:
    1. dc08-1204v1
    2. 31/11/2092 most recent

Current Issue

  1. November 2009, 32 (11)
  1. Current Issue
  1. Alert me to new issues of Diabetes Care